Sentence examples similar to rash injection from inspiring English sources

Kawasaki disease: patients diagnosed with KD had fever for at least 3 days but not more than 10 days, and met at least four of five clinical criteria for KD (rash, conjunctival injection, cervical lymphadenopathy, oral mucosal changes, and changes in the extremities) or three of five criteria and coronary artery abnormalities documented by echocardiogram [ 6].

All KD patients had fever and ≥4 of the five principal clinical criteria for KD (rash, conjunctival injection, cervical lymphadenopathy, changes in the oral mucosa, and changes in the extremities) or three criteria plus coronary artery abnormalities documented by echocardiography [ 27] All FI control, patients had naso- or oro-pharyngeal and stool viral cultures.

In the only published study comparing chikungunya and dengue clinical manifestations in Thailand, the onset of symptoms was more abrupt; the febrile course was shorter; and maculopapular rashes, conjunctival injection, and arthralgia were significantly more frequent than in dengue (12 ).

The aetiology of KD remains unknown, although the clinical presentation self-limiting illness manifested by an abrupresentation self-limitingxanthema, conjunctillnessjection and cervical adenopathy—and the epidemanifested features—a seasonal peak in winter and spring, age distribytion and abruptraphic wave-like spread onsetlness during epidemics—strofgly suggest an infeverous cause [1, 2, 3, 4].

The most common adverse event was rash at the injection site.

Adverse events associated with LIRA were nausea (6/11), diarrhea (6/11), headache (3/11), and rash at the injection site during the first week (1/11).

Among these patients, 68% were older than 60 and started to occur after 6 ~ 8 weeks of the procedure; and (vi) skin: 1% (a localized rash around the injection site after 1 ~ 2 days of the procedure) (Table  4).

Mild side effects can include: Swelling or rash around the injection site (about 1 in 20 people).

This may range from urticarial rash at the injection site to an anaphylactic life threatening reaction, although fortunately this is a rare occurrence.

There was a 0.1% incidence of varicella-like rashes at the injection site of vaccine recipients compared with 0.04% of placebo recipients (P < 0.05) (Oxman et al 2005).

Interestingly, injection-related adverse events such as injection site rash, were not reported in any of the LEAD trials.